Glenmark Pharma reports Q4 FY25 PAT at Rs. 346.6 Cr

Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore

CPHI & PMEC China sees surge in international attendance

Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth

Strides Pharma Q4 net profit rises 5x to Rs. 113 Cr

For the full year FY25, net profit soared 12x to Rs 345 crore

Alembic Pharmaceuticals announces USFDA final approval for Amlodipine and Atorvastatin Tablets USP

Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin

Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025

Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025

Cupid posts Q4 FY25 consolidated PAT at Rs. 11.51 Cr

The company has posted net profit of Rs. 40.88 crores for the Financial Year ended March 31, 2025

Mankind Pharma posts Q4 FY25 consolidated PAT Rs. 425.11 Cr

The company has posted net profit of Rs. 1,986.43 crores for the Financial Year ended March 31, 2025

Merck presents positive Phase 2 data for Enpatoran demonstrating reduction in disease activity in patients with CLE and SLE with active lupus rash

Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8

Marksans Pharma FY25 PAT up 21% at Rs. 382.6 Cr

Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24

Tata 1mg optimises e-commerce operations with Unicommerce